Abstract 47P
Background
In CRC molecular studies have shown that there is a great inter-tumour heterogeneity (ITH) within each UICC TNM stage and therefore a range of other transcriptional and protein biomarkers need to be investigated independently of the UICC TNM staging. In CRC, one of these adverse prognostic factors is tumour budding, Typically, tumour budding is assessed using H&E-stained specimens but scoring methods and grading schemes vary widely. A retrospective study was carried out to study the differential expression of discriminative markers in matched invasion fronts and tumour buds of 44 patients with stage 3/4 CRC disease.
Methods
A retrospective study was done on 44 Formalin Fixed paraffin embedded tissue sections with at least stage 3/4 CRC disease. These cases were used to study the expression differences between the central portion of the tumour, the invasion front and the tumour buds using the Luminex bead-based assay. The different tumoral compartments were assessed by a pathologist on a H&E stained slide and a 0.5mm core was obtained from each respective area on the specimen block. The core was lysed for 18 – 22 hrs at 58°C. After overnight incubation, hybridization-based assay was performed to study the expression of 50 different genes. Data analysis was carried out to see if there is any statistically significant difference between the central portion of the tumour, the invasion front and tumour buds.
Results
A statistically significant differences was noted in the expression of TRIB1 and CCND3 when comparing the central portion of the tumour to the tumour buds. The expression of TRIB1 and CCND3was higher in the buds than that of the central tumour. A statistically significant difference was seen in the expression of CDX2 when comparing the invasion front to the tumour bud. CDX2 was higher in the invasion front than in the tumour buds. A statistically significant difference was also seen in the expression of MCL1 which was higher in the invasion fronts when compared to the central tumour part.
Conclusions
With the use of a bead based multiplex assay we were able to carry out differential expression of a number of genes related to invasiveness, metastasis and treatment resistance in matched central tumour, invasion fronts and tumour buds in CRC patients.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
The authors.
Funding
Emanuele Cancer Research Foundation Malta.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
114P - Circulating microRNAs and response to oncological and surgical therapy in patients with locally advanced gastric cancer
Presenter: Vasileia Kokala-Dimitropoulou
Session: Cocktail & Poster Display session
Resources:
Abstract
115P - BrainStorm-NSE: Serum neuron-specific enolase as a biomarker for central nervous system metastases: A prospective cohort study
Presenter: Diogo Martins-Branco
Session: Cocktail & Poster Display session
Resources:
Abstract
116P - Switching to a multigenic parallel sequencing approach: The landscape of biomarkers profiling changing between immunohistochemistry and next generation sequencing advantages and sustainability from a public hospital in Northern Italy
Presenter: Giulia Ghirardi
Session: Cocktail & Poster Display session
Resources:
Abstract
117P - Homologous recombination deficiency (HRD) by shallow whole genome sequencing (sWGS): Seamless integration in an existing NGS somatic oncology workflow
Presenter: Etienne Muller
Session: Cocktail & Poster Display session
Resources:
Abstract
118P - Molecular diagnostics of gastrointestinal stromal tumors in the era of precision oncology
Presenter: Alena Kalfusova
Session: Cocktail & Poster Display session
Resources:
Abstract
119P - De novo and histologically transformed small-cell lung cancer is sensitive to lurbinectedin treatment through the modulation of EMT and NOTCH signaling pathways
Presenter: Triparna Sen
Session: Cocktail & Poster Display session
Resources:
Abstract
120P - Anti-angiogenic therapy or immunotherapy? A multicenter real-world study of patients with advanced non-small cell lung cancer with EGFR / HER2 exon 20 insertion mutations
Presenter: Tianqing Chu
Session: Cocktail & Poster Display session
Resources:
Abstract
121P - Clinical outcomes of compound EGFR mutation in non-small cell lung cancer: A national, retrospective, multicenter study
Presenter: Aurélien Brindel
Session: Cocktail & Poster Display session
Resources:
Abstract
122P - Molecular testing, treatment, and response of patients with advanced solid tumors harboring an NTRK gene fusion: Second interim results of the REALTRK registry
Presenter: Sebastian Lange
Session: Cocktail & Poster Display session
Resources:
Abstract
123P - Incidence and outcomes of anaplastic lymphoma kinase (ALK) and ROS 1 positive advanced NSCLC: A real world experience
Presenter: Stalin Chowdary Bala
Session: Cocktail & Poster Display session
Resources:
Abstract